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Abstract

Background Multiple studies suggested that celiac disease (CD) may be associated with microscopic
colitis (MC); however, most were limited by a small sample size or the main scope of interest. We aimed
to analyze previously published literature on this association to determine its extent and significance.
Methods A systematic review was conducted in PubMed, Embase, PubMed Central, Cochrane,
and ScienceDirect databases from inception through January 2022. The PRISMA guideline was
followed for data extraction. Effect estimates were extracted and combined using random effect,
the generic inverse variance method of DerSimonian and Laird and pooled odds ratio (OR), and
event rates (ER) were calculated. The Newcastle-Ottawa scale was used to evaluate the risk of bias.
Forest plots were generated and publication bias assessed via conventional techniques.
Results Twenty-six studies with a total of 22,802 patients with MC were included in this
analysis. CD was significantly associated with MC (odds ratio [OR] 8.276, 95% confidence
interval [CI] 5.888-11.632; P<0.001). The ER for MC in CD patients was 6.2% (95%CI 4.1-9.2%;
P<0.001), while the ER for CD in MC patients was 6.1% (95%CI 3.9-9.5%; P<0.001). CD was
prevalent in both types of MC: 5.2% (95%CI 2.2-12.1%; P<0.001) in collagenous colitis and 6.3%
(95%CI 3.4-11.5%; P<0.001) in lymphocytic colitis. We found no publication bias, according to
funnel plots and Egger’s regression asymmetry testing.
Conclusions Our meta-analysis confirms a statistically significant association between CD and
MC, with a high prevalence of CD in both types of MC. Gastroenterologists should be wary of this
association when evaluating patients with either disease, particularly patients with a suboptimal
response to first-line therapy.
Keywords Microscopic colitis, celiac disease, lymphocytic colitis, collagenous colitis, autoimmune
diseases

Ann Gastroenterol 2022; 35 (1): 1-9

a

Introduction

Conflict of Interest: None

DOI: https://doi.org/10.20524/aog.2022.0714

Microscopic colitis (MC) is an inflammatory condition
in which patients suffer from chronic diarrhea with evidence
of chronic inflammation under the microscope, but show
normal colonic morphology macroscopically [1]. MC was first
suggested as a cause of chronic diarrhea of an unknown etiology
by Read et al in 1980 [2]. MC piqued our interest, given the
normal endoscopic findings [3,4], and since then there have
been many advances in characterizing and classifying MC. MC
is subclassified into collagenous colitis (CC) and lymphocytic
colitis (LC). LC is diagnosed with intraepithelial lymphocytes
elevated to at least >20 lymphocytes per 100 cells, without
distortion of crypt architecture. CCs differ histologically,
showing a more than 10-μm collagen band in the subepithelial
layer, absent in LC [5,6]. Since the 2 variants overlap in
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clinical presentation, presumed pathophysiology and clinical
course [7,8], they were eventually joined into one disease
entity, MC.
MC is not an uncommon disease. A meta-analysis by
Tong et al found pooled incidence rates of 4.14 and 4.85 per
100,000 person-years for CC and LC, respectively. The same
study also showed that MC is more common in females than
males, with an incidence ratio of 3.05:1 for CC and 1.92:1
for LC. The median age of onset is approximately 65 years
for CC and 62 years for LC [9-11]. The exact pathogenesis
and development of MC are still poorly understood, but
multiple studies have suggested an association between
MC and multiple different autoimmune diseases within the
gastrointestinal (GI) tract, as well as in other organ systems,
with the suggestion that these conditions share a similar
underlying pathophysiology [12,13]. Type 1 diabetes mellitus
and autoimmune thyroiditis are autoimmune diseases that are
commonly concurrent with MC outside the GI tract [1,14].
Different studies have also shown some correlation between
MC and multiple lymphocytic inflammatory disorders of the
GI tract, including lymphocytic esophagitis, lymphocytic
gastritis, duodenal intraepithelial lymphocytosis, and celiac
disease (CD) [15,16]. Koskela et al showed that tumor necrosis
factor (TNF) α and human leukocyte antigen (HLA) DR3-DQ2
haplotype have a role in the pathogenesis and development
of MC, and suggested a strong association of MC with CD
and other autoimmune lymphocytic disorders [1,7,14,15,17].
Other studies have shown elevated levels of interferon (IFN)
γ, interleukin (IL) 15, TNF, and nitric oxide synthase levels
in MC, proposing that the dysfunctional activation of the
immune system and immunological pathophysiology are
similar to other autoimmune diseases [18].
Furthermore, Westerlind et al and Stahl et al investigated
the association between MC variants, CC and LC, and certain
HLA regions in the human genome, where it was found that
patients with specific HLA variants, such as HLA-B∗08:01,
HLA-DRB1∗03:01 and HLA-DQB1∗02:01, have greater risk of
developing CC, while HLA-DRB1∗04:01 has a protective effect
against CC [19,20]. These findings helped towards a better
understanding of the pathophysiology and immunogenicity of
MC and suggests that MC can be related to other autoimmune
diseases where specific HLA alleles are important or associated
with disease development, such as CD and inflammatory
bowel disease. Westerlind et al also studied whether there
is any association between LC and specific HLA alleles,
similar to those with CC, but found none; accordingly, they
suggested that HLA association can differentiate between CC
and LC, which may suggest differences in pathophysiological
development [21].
CD is an immune-mediated disease of the small bowel
attributable to gluten sensitivity in susceptible patients [12,22].
It is characterized by chronic diarrhea, malabsorption, weight
loss, bloating, abdominal pain, and, as a result, failure to
thrive [23,24]. CD is diagnosed by the presence of clinical
symptoms, serological markers and histological examination
of intestinal biopsies [25-29]. Histological evaluation typically
shows a spectrum of disease, ranging from intraepithelial
lymphocytosis to total mucosal damage characterized by
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atrophy and loss of villi, hyperplasia of the crypts and increased
apoptosis of the epithelium [30-32]. The pathogenesis of CD
includes gluten antigen presented on the surface of HLA
complexes, mainly of haplotypes DQ2 or DQ8 [17,33,34].
Although multiple studies have proposed that MC and CD
show significant correlation and have similar pathophysiological
development, these studies were limited by their small sample
sizes or scope of interest [35,36]. Establishing an association
between such immune-mediated diseases would suggest a
need for screening of concomitant pathologies, or altering the
management of these patients, especially if they fail to respond
to first-line therapy. Therefore, we conducted a broad-based
systematic review and meta-analysis to study the association
between MC and CD.

Materials and methods
Literature search and study selection

A comprehensive broad-based literature search in PubMed
Central, PubMed, Embase, Cochrane, and ScienceDirect
databases, from inception through January 2022, was conducted
to identify all observational studies examining the association
between MC and CD. The following keywords were used in
different combinations: microscopic colitis, collagenous colitis,
lymphocytic colitis, celiac disease, celiac sprue, autoimmune,
enteropathy. Our search was limited to human studies only, but
was not confined to any language, or region.
Data extraction and quality assessment

We included studies that evaluated the association between
MC and CD if they presented an odds ratio (OR) for our main
outcome with a 95% confidence interval (CI), or an event rate
for our outcomes, or presented data sufficient to calculate these
variables. Studies were excluded if they were letters to editors,
case reports, case series, review articles or if they provided
insufficient information to calculate the event rates and/or the
OR for our main outcome.
The authors (LA and FN) performed the literature review
independently. The data extracted from the studies included
first author, year of publication, country, study design, and
quantitative estimates, including event rates or ORs with
95%CIs for the association of MC with CD. The risk of internal
bias was assessed using the Newcastle-Ottawa scale [37].
Statistical analysis

Statistical analysis was performed using the comprehensive
meta-analysis (CMA) software, version 3 (BioStat, Inc.,
Eaglewood, NJ, USA). Effect estimates from the individual
studies were extracted and combined using the randomeffect, generic inverse variance method of DerSimonian
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and Laird [38]. A random-effect model was used, as a high
probability of between-study variance, due to variations in
study population and methodology, was suspected. A pooled
event rate or pooled OR was calculated. A Cochran’s Q-test was
used to evaluate heterogeneity and quantify variation across
the selected studies [39]. A funnel plot was then created to
evaluate for publication and other reporting biases. The plot
was examined visually for asymmetry and an Egger test for
asymmetry was also conducted.

Results
Search results

The PRISMA study flowchart is shown in Fig. 1. A total of
367 articles were retrieved. After review of titles and abstracts,
310 articles were excluded as they did not meet the eligibility
criteria, leaving 57 articles for full-text review. A further 31
articles were excluded, because 17 did not include the necessary
data, 8 were case series and 6 had no full text available for review.
This left 6 cross-sectional studies, 15 cohort studies and 5 casecontrol studies to be included in the analysis [11,13-16,40-60].
Study characteristics

Citations identified through
database searching
(n=367)

Eligibility

Screening

Identification

Table 1 summarizes the studies that assessed the event
rates of CD in patients with MC, and Table 2 summarizes
those that assessed the event rates of MC in patients with
CD. A total of 26 studies were published between the years
1997 and 2021. Seven studies were conducted in the United
States [14,15,47,50,55,59,60], 4 in Sweden [11,16,48,52], 3 in
Canada [41,42,54], 3 in the United Kingdom [43,57,58], 3 in The
Netherlands [45,53,56], 1 in Finland [46], 1 in Hungary [40], 1
in Italy [51], 1 in Ireland [49], 1 in Denmark [13], and 1 in

Spain [44]. A total of 4640 study participants were included.
A case-control study by Wildt et al, conducted in Denmark in
2021, included the largest number of cases, more than 15,500
in total [13].
Association of MC and CD

In our meta-analysis, we have found that CD is significantly
associated with MC, with pooled OR 8.276 (95%CI 5.88811.632; P<0.001) (Fig. 2). A total of 22571 MC cases were
included, of which 513 patients were found to have concurrent
CD with a pooled event rate for CD in patients with MC of
6.1% (95%CI 3.9-9.5%; P<0.001), Fig. 3. CD was also found to
be prevalent in both subtypes of MC individually; with a pooled
event rate of 5.2% (95%CI 2.2-12.1%; P<0.001) in patients with
CC (Fig. 4), and 6.3% (95%CI 3.4-11.5%; P<0.001) in patients
with LC (Fig. 5).
A total of 3593 CD cases were included, of which
231 patients were found to have concurrent MC, with a pooled
event rate for MC in patients with CD of 6.2% (95%CI 4.1-9.2%;
P<0.001) (Fig. 6). When both subtypes of MC were evaluated
individually in patients with CD, it was found that CC and LC
were prevalent in CD; with pooled event rate of 1.6% (95%CI
0.7-3.5%; P<0.001) in CC (Fig. 7), and 4.3% (95%CI 3.1-5.9%;
P<0.001) in LC (Fig. 8).
Evaluation for publication bias

To evaluate for the presence of publication bias a funnel
plot was generated to evaluate the association between MC and
CD (Fig. 9,10). The plot for all studies is symmetric and does
not suggest the presence of publication bias. Egger’s regression
asymmetry testing was also performed to demonstrate no
evidence of publication bias (P=0.79).
Citations added from other
resources
(n=0)

Screened Citations
(n=367)

Full-text studies reviewed for qualification
(n=57)

Studies eligible for qualitative analysis
(n=26)
Included

Citations excluded (n=310)
after review of title, study
design and eligibility

Citations excluded (n=31)
- 17 didn't include enough data
for analysis.
- 8 were case series.
- 6 with no full-text available
for review

Studies included in qualitative analysis
(Meta-Analysis)
(n=26)

Figure 1 PRISMA study flowchart
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Table 1 Summary of studies assessing celiac disease event rate in patients with microscopic colitis
Study [ref.]

Type of study

Origin, year
of the study

CD
cases

MC
cases

OR/RR/SMR
(CD in MC)

P‑value for
OR/RR/SMR

Event rate

P‑value for
event rate

Barta
et al [40]

Retrospective
cohort study

Hungary, 2005

2

53

N/A

N/A

0.038
(0.009‑0.139)

0.001

Freeman
et al [41]

Retrospective
cohort study

Canada, 2004

8

36

N/A

N/A

0.222
(0.115‑0.385)

0.002

Gillet
et al [42]

Cross‑sectional
study

Canada, 2000

4

23

N/A

N/A

0.174
(0.067‑0.382)

0.005

Green
et al [43]

Retrospective
cohort study

UK, 2019

16

483

OR 7.7
(4.7‑12.6)

<0.001

0.033
(0.020‑0.053)

0.001

Guagnozzi
et al [44]

Case‑control study

Spain, 2015

6

46

OR 15.3
(3.7‑63.4)

<0.001

0.130
(0.060‑0.261)

0.001

Jobse
et al [45]

Retrospective
cohort study

Netherlands,
2009

2

83

N/A

N/A

0.024
(0.006‑0.091)

0.001

Kao
et al [14]

Retrospective
cohort study

USA, 2009

18

547

N/A

N/A

0.033
(0.021‑0.052)

0.001

Koskela
et al [46]

Case‑control study

Finland, 2004

14

84

OR 16.6
(2.2‑127.5)

0.007

0.167
(0.101‑0.262)

0.001

Matteoni
et al [47]

Cross‑sectional
study

USA, 2001

4

46

N/A

N/A

0.035
(0.013‑0.091)

0.001

Mellander
et al [11]

Retrospective
cohort study

Sweden, 2016

48

795

N/A

N/A

0.060
(0.046‑0.079)

0.001

Olesen
et al [48]

Retrospective
cohort study

Sweden, 2004

17

199

N/A

N/A

0.085
(0.054‑0.133)

0.001

O’Toole
et al [49]

Retrospective
cohort study

Ireland, 2014

26

222

N/A

N/A

0.117
(0.081‑0.166)

0.001

Pardi
et al [50]

Retrospective
cohort study

USA, 2002

10

170

N/A

N/A

0.059
(0.032‑0.106)

0.001

Wildt
et al.[13]

Case‑control study

Denmark,
2021

180

15597

OR 10.15
(8.20‑12.6)

<0.001

0.012
(0.010‑0.013)

0.001

Simondi
et al [51]

Retrospective
cohort study

Italy, 2010

4

80

N/A

N/A

0.05
(0.019‑0.126)

0.001

Sonnenberg
et al [15]

Cross‑sectional
study

USA, 2018

109

3456

RR 6.06
(5.06‑7.25)

<0.001

0.032
(0.026‑0.038)

0.001

Svensson
et al [52]

Retrospective
cohort study

Sweden, 2018

12

200

N/A

N/A

0.060
(0.034‑0.103)

0.001

Verhaegh
et al [53]

Case‑control study

The
Netherlands,
2017

6

171

OR 10.86
(1.3‑91.4)

0.028

0.035
(0.016‑0.076)

0.001

Vigren
et al [16]

Retrospective
cohort study

Sweden, 2013

15

116

N/A

N/A

0.129
(0.079‑0.203)

0.001

Williams
et al [54]

Retrospective
cohort study

Canada, 2008

12

164

RR 7.9
(4.0‑14.2)

<0.001

0.073
(0.042‑0.124)

0.001

513

22571

8.276
(5.888‑11.632)

<0.001

0.061
(0.039‑0.095)

0.001

All CD in
MC

CD, celiac disease; MC, microscopic colitis; OR, odds ratio; RR, relative risk; SMR, standardized mortality/morbidity risk; USA, United States of America;
UK, United Kingdom; N/A, not available

Discussion
Chronic diarrhea is defined as soft stool consistency and/
or increased stool frequency with stool volume of more than
Annals of Gastroenterology 35

200 g/24h [61]. Chronic diarrhea is a very common complaint
that patients present with to the primary care or gastroenterology
clinics; it can be very unpleasant and debilitating. In many cases,
patients undergo an extensive workup in order to discover the
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Table 2 Summary of studies assessing microscopic colitis event rate in celiac disease patients
Study [ref.]

Type of study

Origin of the
study

MC
cases

CD
cases

OR/RR/SMR
(MC in CD)

P‑value

Event rate

P‑value

Green et al
[55]

Cross‑sectional
study

USA, 2009

44

1009

SMR 45.5
(27.7‑63.3)

<0.05

0.044 (0.033‑0.058)

<0.001

Spijkerman
et al [56]

Cross‑sectional
study

The
Netherlands,
2016

20

412

N/A

N/A

0.049 (0.032‑0.074)

<0.001

Dewar et al
[57]

Prospective
cohort study

UK, 2012

11

100

N/A

N/A

0.110 (0.062‑0.188)

<0.001

Leeds et al
[58]

Case‑control
study

UK, 2007

5

305

N/A

N/A

0.016 (0.007‑0.039)

<0.001

Leffler et al
[59]

Cross‑sectional
study

USA, 2007

6

113

N/A

N/A

0.053 (0.024‑0.113)

<0.001

Sonnenberg
et al [15]

Cross‑sectional
study

USA, 2018

134

1576

N/A

N/A

0.085 (0.072‑0.100)

<0.001

Fine et al
[60]

Prospective
cohort study

USA, 1997

11

78

N/A

N/A

0.141 (0.080‑0.237)

<0.001

231

3593

N/A

N/A

0.062 (0.041‑0.092)

<0.001

All MC in
CD

CD, celiac disease; MC, microscopic colitis; OR, odds ratio; RR, relative risk; SMR, standardized mortality/morbidity risk; USA, United States of America; UK,
United Kingdom; N/A, not available
Study name

Statistics for each study
Odds Lower Upper
ratio limit
limit Z-Value p-Value
Sonnenberg et al (2018) [15] 6.060 5.063 7.254 19.638 <0.001
Guagnozzi et al (2015) [44] 15.300 3.693 63.384
3.762 <0.001
Verhaegh et al (2017) [53] 10.860 1.291 91.378
2.195 0.028
Koskela et al (2004) [46]
16.600 2.162 127.484
2.701 0.007
Wildt et al (2021) [13]
10.150 8.188 12.582 21.148 <0.001
Green et al (2019) [43]
7.720 4.681 12.731
8.007 <0.001
8.276 5.888 11.632 12.167 <0.001

Odds ratio and 95% CI

0.01
0.1
1
10
100
Non-celiac Disease Celiac Disease

Figure 2 Forest plot of the meta-analysis of the odds ratio for celiac disease in patients with microscopic colitis

etiology, including multiple endoscopies and frequent repeat
imaging [62]. The initial workup includes complete blood count,
thyroid-stimulating hormone levels, basic metabolic profile,
stool for occult blood, infectious workup as indicated, CD
serologies, fecal calprotectin and inflammatory markers [63].
Despite an extensive workup and multiple treatments, some
patients continue to suffer from chronic diarrhea without
significant improvement. Many patients have also been found
to have multiple concomitant pathologies, which might lead to
persistence of symptoms regardless of the treatment of a single
etiology. Accordingly, we studied the association between 2
common causes of chronic diarrhea, MC and CD.
The present study is the first systematic review and metaanalysis to summarize the results of all available observational
studies that reported an association between MC and CD.
In this meta-analysis, we found that CD was significantly
associated with MC (OR 6.221, 95%CI 3.828-10.108; P<0.001).
The pooled event rate for MC in patients with CD was 6.7%
(95%CI 4.4-10.0%; P<0.001), while the pooled event rate

for CD in patients with MC was 7.7% (95%CI 4.6-12.6%;
P<0.001). CD was prevalent in both types of MC: 5.4% (95%CI
1.3-20%; P<0.001) for CC and 9.1% (95%CI 4.5-17.3%;
P<0.001) for LC. The study by Sonnenberg et al (2018) was the
largest cross-sectional study included in our analysis, involving
3456 patients with MC, 1864 with the LC subtype and 1592
with the CC subtype [15].
The underlying mechanism of the association between MC
and CD is still unclarified. Some studies have suggested that
the diseases have very similar immunological development, as
both are associated with elevated levels of certain inflammatory
markers and specific cytokines, including IFN-γ, TNF, and IL15. Other studies have found similar HLA complexes involved
in the development of both diseases and have suggested an
association between CD and MC.
As reported in the literature, immune-mediated diseases
are frequently found concomitantly [64,65]. It is also wellestablished in the literature that most immune diseases are
more common in females [66].
Annals of Gastroenterology 35
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Study name

Event rate and 95% CI

Statistics for each study
Event Lower Upper
rate limit limit Z-Value p-Value

Sonnenberg et al (2018) [15]
Guagnozzi et al (2015) [44]
Williams et al (2008) [54]
Matteoni et al (2001) [47]
Verhaegh et al (2017) [53]
Simondi et al (2010) [51]
Olesen et al (2004) [48]
Koskela et al (2004) [46]
Freeman et al (2004) [41]
Gillett et al (2000) [42]
Barta et al (2005) [40]
Green et al (2019) [43]
Jobse et al (2009) [45]
Kao et al (2009) [14]
Mellander et al (2016) [11]
O'Toole et al (2014) [49]
Pardi et al (2002) [50]
Svensson et al (2018) [52]
Vigren et al (2013) [16]
Wildt et al (2021) [13]

0.032
0.130
0.073
0.035
0.035
0.050
0.085
0.167
0.222
0.174
0.038
0.033
0.024
0.033
0.060
0.117
0.059
0.060
0.129
0.012
0.061

0.026
0.060
0.042
0.013
0.016
0.019
0.054
0.101
0.115
0.067
0.009
0.020
0.006
0.021
0.046
0.081
0.032
0.034
0.079
0.010
0.039

0.038
0.261
0.124
0.091
0.076
0.126
0.133
0.262
0.385
0.382
0.139
0.053
0.091
0.052
0.079
0.166
0.106
0.103
0.203
0.013
0.095

-35.184
-4 333
-8.467
-6.492
-7.974
-5.740
-9 348
-5.497
-3.125
-2.832
-4.493
-13.270
-5.171
-14.105
-18.434
-9.678
-8.506
-9.241
-6.892
-59.361
-11.429

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
0.005
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
-1.00

-0.50

0.00

Non-celiac Disease

0.50

1.00

Celiac Disease

Figure 3 Forest plot of the meta-analysis of the event rates for celiac disease in patients with microscopic colitis

Study name

Statistics for each study

Event
rate
Freeman et al (2004) [41]
0.222
Gillet et al (2000) [42]
0.056
Koskela et al (2004) [46]
0.200
Matteoni et al (2001) [47)
0.025
Sonnenberg et al (2018) [15] 0.026
Jobse et al (2009) [45]
0.024
Kao et al (2009) [14]
0.029
Vigren et al (2013) [16]
0.129
Wildt et al (2021) [13]
0.011
0.052

Lower
limit
0.115
0.003
0.093
0.002
0.020
0.006
0.012
0.079
0.009
0.022

Upper
limit Z-Value
0.385 -3.125
0.505 -1.947
0.379 -3.037
0.298 -2.558
0.036 -23.074
0.091 -5.171
0.068 -7.717
0.203 -6.892
0.013 -44.723
0.121 -6.204

Odds rate and 95% CI

p-Value
0.002
0.052
0.002
0.011
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
-1.00 -0.50 0.00
0.50
1.00
Non-celiac Disease Celiac Disease

Figure 4 Forest plot of the meta-analysis of the event rates for celiac disease in patients with collagenous colitis

Study name

Statistics for each study

Event rate and 95% CI

Event Lower Upper
rate limit
limit Z-Value p-Value
Gillet et al (2000) [42]
0.267 0.104 0.533 -1.733 0.083
Koskela et al (2004) [46]
0.148 0.076 0.269 -4.566 <0.001
Matteoni et al (2001) [47]
0.148 0.057 0.335 -3.229 0.001
Olesen et al (2004) [48]
0.085 0.054 0.133 -9.348 <0.001
Simondi et al (2010)[51]
0.050 0.019 0.126 -5.740 <0.001
Sonnenberg et al (2018) [15] 0.036 0.028 0.045 -26.435 <0.001
Kao et al (2009) [14]
0.035 0.020 0.059 -11.795 <0.001
Pardi et al (2002) [50]
0.059 0.032 0.106 -8.506 <0.001
Wildt et al (2021) [13]
0.013 0.010 0.016 -38.943 <0.001
0.063 0.034 0.115 -8.029 <0.001
-1.00 -0.50 0.00
0.50
1.00
Non-celiac Disease Celiac Disease

Figure 5 Forest plot of the meta-analysis of the event rates for celiac disease in patients with lymphocytic colitis
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Study name

Statistics for each study

Event rate and 95% CI

Event Lower Upper
rate limit
limit Z-Value p-Value
Green et al (2009) [43]
0.044 0.033 0.058 -20.031 <0.001
Spijkerman et al (2016) [56] 0.049 0.032 0.074 -12.980 <0.001
Fine et al (1997) [60]
0.141 0.080 0.237 -5.554 <0.001
Leffler et al (2007) [59]
0.053 0.024 0.113 -6.867 <0.001
Sonnerberg et al (2018) [15] 0.085 0.072 0.100 -26.308 <0.001
Dewar et al (2012) [57]
0.110 0.062 0.188 -6.542 <0.001
Leeds et al (2007) [58]
0.016 0.007 0.039 -9.080 <0.001
0.062 0.041 0.092 -12.498 <0.001
-1.00

-0.50

0.00

0.50

1.00

No Microscopic Colitis Microscopic Disease

Figure 6 Forest plot of the meta-analysis of the event rates for microscopic colitis in patients with celiac disease

Study name

Statistics for each study

Event rate and 95% CI

Event Lower Upper
rate limit limit Z-Value p-Value
0.011 0.006 0.020 -14.869 <0.001
Green et al (2009) [43]
0.010 0.005 0.021 -12.794 <0.001
Stewart et al (2011) [67]
Sonnenberg et al (2018) [15] 0.030 0.023 0.040 -23.607 <0.001
0.016 0.007 0.035 -9.885 <0.001
-0.25

-0.13

0.00

0.13

0.25

No Collagenous Colitis Collagenous Disease

Figure 7 Forest plot of the meta-analysis of the event rates for collagenous colitis in patients with celiac disease

Study name

Statistics for each study

Event
rate
0.033
Green et al (2009) [43]
0.042
Stewart et al (2011) [67]
Sonnenberg et al (2018) [15] 0.055
0.043

Lower
limit
0.023
0.030
0.044
0.031

Upper
limit
0.046
0.059
0.067
0.059

Event rate and 95% CI

Z-Value p-Value
-19.136
-17.323
-25.718
-18.657

<0.001
<0.001
<0.001
<0.001
-0.25

-0.13

0.00

0.13

0.25

No Lymphocytic Colitis Lymphocytic Disease

Figure 8 Forest plot of the meta-analysis of the event rates for lymphocytic colitis in patients with celiac disease
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Figure 9 Funnel plot of the meta-analysis of the risk of celiac disease in
patients with microscopic colitis
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Figure 10 Funnel plot of the meta-analysis of the risk of microscopic
colitis in patients with celiac disease
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The 8 studies in our meta-analysis included largely diverse
populations from different continents, suggesting that, even
with the genetic and environmental variations among different
populations, there is still a significant association between
MC and CD. This also reinforces the theory that similar
immunological evolution led to the emergence of both diseases.
Although most patients with CD usually respond to treatment,
a subset of patients partially respond or continue to have similar
symptoms despite strict dietary modification. Similarly, in MC
a large number may respond to first-line therapy, while others
may not. In such patients with refractory disease, a second
concomitant pathology should be suspected and investigated
accordingly. Thus, establishing an association between MC and
CD might be practice-changing and even life-changing.
In summary, our meta-analysis confirms a statistically
significant association between CD and MC, with a high
prevalence of CD in both subtypes of MC. Gastroenterologists
should be wary of this association when evaluating patients
with either disease, particularly in patients with a suboptimal
response to first-line therapy.

Summary Box
What is already known:

• Microscopic colitis (MC) can cause chronic diarrhea
and is diagnosed by histopathology showing large
numbers of intraepithelial lymphocytes, with more
than 20 lymphocytes per high power field
• MC is subdivided into collagenous and lymphocytic
colitis
• MC is associated with autoimmune diseases
• Celiac disease (CD) is an autoimmune disease
secondary to gluten sensitivity and can cause chronic
diarrhea, malabsorption, weight loss, and bloating
What the new findings are:

• MC is significantly associated with CD
• The pathophysiology of MC can be similar to that
of other autoimmune disease, such as CD, given this
significant association
• Patients with chronic diarrhea who show a
suboptimal response to first-line therapy should be
investigated for a secondary process
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